Cameron Woodlief, MD
Internal Medicine · Reynoldsburg, OHNPI 1922083633
Payments from drug & device makers
Across 327 payments — averaging $15.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$753
- Novo Nordisk$641
- AbbVie$383
- Pfizer$331
- Lilly USA, LLC$301
- Boehringer Ingelheim$258
- plus $2K from 28 others
What the payments were for
- Food & beverage$5,04398%
- Education$862%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 50 | $753 |
| Novo Nordisk | 43 | $641 |
| AbbVie(2 entities) | 21 | $383 |
| Pfizer | 22 | $331 |
| Lilly USA, LLC | 20 | $301 |
| Boehringer Ingelheim | 19 | $258 |
| GSK | 15 | $222 |
| Sanofi-aventis U.S. LLC | 15 | $218 |
| Amarin Pharma, Inc. | 16 | $216 |
| Johnson & Johnson | 16 | $213 |
| Amgen | 13 | $211 |
| Merck | 13 | $182 |
| Xeris Pharmaceuticals, Inc. | 8 | $176 |
| Bayer | 12 | $174 |
| Exact Sciences | 7 | $172 |
| Astellas Pharma US Inc | 5 | $82 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $81 |
| Otsuka America Pharmaceutical, Inc. | 3 | $58 |
| QOL Medical, LLC | 2 | $57 |
| Phathom Pharmaceuticals, Inc. | 3 | $54 |
| Medtronic | 2 | $48 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $45 |
| Dynavax Technologies Corporation | 2 | $43 |
| Dexcom, Inc. | 2 | $41 |
| Insulet Corporation | 1 | $26 |
| Abbott | 1 | $24 |
| Vivus LLC | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Aimmune Therapeutics, Inc. | 1 | $18 |
| Novartis | 1 | $18 |
| Eisai Inc. | 1 | $15 |
| Ironwood Pharmaceuticals, Inc | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
| Sumitomo Pharma America, Inc. | 1 | $1 |
How this compares
$5,129 in reported general payments places this provider in the 90th percentile of 4,428 internal medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 164 | $198,051 |
| EliquisApixaban | 165 | $186,825 |
| OzempicSemaglutide | 124 | $176,332 |
| MounjaroTirzepatide | 86 | $93,852 |
| TrulicityDulaglutide | 65 | $89,606 |
| XareltoRivaroxaban | 61 | $79,582 |
| JanuviaSitagliptin Phosphate | 51 | $46,925 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $45,037 |
| FarxigaDapagliflozin Propanediol | 29 | $34,868 |
| Tresiba Flextouch U-200Insulin Degludec | 34 | $33,619 |
| Bydureon BciseExenatide Microspheres | 18 | $32,705 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 84 | $26,836 |
| RybelsusSemaglutide | 16 | $25,821 |
| MyrbetriqMirabegron | 23 | $23,315 |
| VascepaIcosapent Ethyl | 20 | $18,803 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $331 | $213,661249 claims |
| Novo NordiskOzempic, Rybelsus | $641 | $202,153140 claims |
| Boehringer IngelheimJardiance | $258 | $198,051164 claims |
| Lilly USA, LLCMounjaro, Trulicity | $301 | $183,458151 claims |
| Johnson & JohnsonXarelto, Invokana | $213 | $97,19674 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Shingrix | $222 | $70,65899 claims |
| MerckJanuvia, Janumet Xr | $182 | $62,94368 claims |
| AstraZenecaFarxiga | $753 | $34,86829 claims |
| Astellas Pharma US IncMyrbetriq | $82 | $23,31523 claims |
| AbbVieLinzess, Synthroid | $383 | $18,518101 claims |
| BayerKerendia | $174 | $15,28212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,428 internal medicine providers in Ohio.
Other internal medicine in Reynoldsburg
- Antoinette PragalosCincinnati$27.8M
- Steven FolkerthBeavercreek$9.1M
- Charles EgerCincinnati$8.7M
- Vadim KoshkinCleveland$6.1M
- Nizar DaboulMaumee$4.7M
- Douglas LoganCincinnati$4.7M
- Seref BornovaliLoveland$4.4M
- Yevgeniy BukhmanCanton$3.7M
- Leela VrishabhendraCincinnati$3.4M
- Narinder SainiSpringfield$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.